The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Tandem Diabetes Care
Tandem continues to deliver more options, benefits for those with diabetes
It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the flagship t:slim X2 and the Mobi miniature durable pump — that feature sophisticated software and connectivity to the market’s leading […]
Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
A new study showed improved glucose control in pregnant women using Tandem Diabetes Care (Nasdaq:TNDM) insulin delivery technology. The study showed that pregnant women with type 1 diabetes stayed in the target glucose range for pregnancy more with the Tandem t:slim X2 automated insulin delivery system with Control-IQ technology compared to standard insulin delivery with injections […]
Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
Tandem Diabetes Care (Nasdaq:TNDM) announced today that its t:slim X2 system now works with the Abbott (NYSE:ABT) FreeStyle Libre 3 Plus. This marks the latest pairing of automated insulin delivery (AID) and continuous glucose monitor (CGM) technologies between the companies. They announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in […]
Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
Tandem Diabetes Care (Nasdaq:TNDM) today announced an agreement to develop and commercialize diabetes tech with Abbott (NYSE:ABT). San Diego–based Tandem said it agreed to combine its insulin delivery systems with Abbott’s future dual glucose-ketone sensor. The companies aim to provide more options for people to manage their diabetes. This marks the second recent collaboration announcement […]
Tandem agrees to pay $36M to settle Roche patent litigation
Tandem Diabetes Care (Nasdaq:TNDM) recently filed an SEC Form 8-K announcing its entry into a patent litigation settlement with Roche. The two companies entered into a settlement, mutual release and cross-license agreement. It resolves all actual or potential patent disputes as of May 21. According to the SEC filing, the settlement relates to Tandem’s t:slim […]
Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K to state that it received CE mark for its Mobi insulin delivery system. San Diego-based Tandem can now market the miniature, durable automated insulin delivery system with Control-IQ+ technology in Europe. According to the filing, the company intends to pursue additional regulatory and pre-commercial activities now. […]
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
Tandem Diabetes Care (Nasdaq:TNDM) shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won FDA 510(k) clearance for a new infusion set. The company won clearance for its SteadiSet Infusion Set, according to an SEC Form 8-K. It’s a wearable infusion set that delivers insulin from an insulin pump to the body. San Diego-based […]
Tandem stock rises after hours on Q1 sales beat
Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after the market closed today on first-quarter results that beat the consensus forecast. Shares of TNDM ticked up 6.2% to $17.89 apiece in post-market trading today. The San Diego-based automated insulin delivery technology company reported losses of $130.56 million. That equals 1.97 per share on sales of […]
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
